Effect of Human Mesenchymal Stem Cells on Xenogeneic T and B Cells Isolated from Lupus-Prone MRL.Fas(lpr) Miceopen access
- Authors
- Lee, Hong Kyung; Kim, Eun Young; Kim, Hyung Sook; Park, Eun Jae; Lee, Hye Jin; Lee, Tae Yong; Kim, Kyung Suk; Bae, Sang-Cheol; Hong, Jin Tae; Kim, Youngsoo; Han, Sang-Bae
- Issue Date
- Mar-2020
- Publisher
- HINDAWI LTD
- Citation
- STEM CELLS INTERNATIONAL, v.2020, pp.1 - 10
- Indexed
- SCIE
SCOPUS
- Journal Title
- STEM CELLS INTERNATIONAL
- Volume
- 2020
- Start Page
- 1
- End Page
- 10
- URI
- https://scholarworks.bwise.kr/hanyang/handle/2021.sw.hanyang/10643
- DOI
- 10.1155/2020/5617192
- ISSN
- 1687-966X
- Abstract
- Systemic lupus erythematosus (SLE) is an autoimmune disease, which is characterized by hyperactivation of T and B cells. Human mesenchymal stem cells (hMSCs) ameliorate the progression of SLE in preclinical studies using lupus-prone MRL.Fas(lpr) mice. However, whether hMSCs inhibit the functions of xenogeneic mouse T and B cells is not clear. To address this issue, we examined the in vitro effects of hMSCs on T and B cells isolated from MRL.Fas(lpr) mice. Naive hMSCs inhibited the functions of T cells but not B cells. hMSCs preconditioned with IFN-gamma (i) inhibited the proliferation of and IgM production by B cells, (ii) attracted B cells for cell-cell interactions in a CXCL10-dependent manner, and (iii) inhibited B cells by producing indoleamine 2,3-dioxygenase. In summary, our data demonstrate that hMSCs exert therapeutic activity in mice in three steps: first, naive hMSCs inhibit the functions of T cells, hMSCs are then activated by IFN-gamma, and finally, they inhibit B cells.
- Files in This Item
-
- Appears in
Collections - 서울 의과대학 > 서울 내과학교실 > 1. Journal Articles
![qrcode](https://api.qrserver.com/v1/create-qr-code/?size=55x55&data=https://scholarworks.bwise.kr/hanyang/handle/2021.sw.hanyang/10643)
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.